Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.39 |
| ▸ | RAD51 | Q06609 | 4/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | GLA | P06280 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PRNP | P04156 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17620550 | 0.90 | TDP1 (0.47) | MAPTKDM4ENPC1RAB9ARAD51 | |
| SCHEMBL17620574 | 0.83 | ALDH1A1 (0.51) | MAPTKDM4ENPC1RAB9ARAD51 | |
| SCHEMBL17620539 | 0.82 | L3MBTL1 (0.52) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL17634375 | 0.82 | L3MBTL1 (0.43) | MAPTKDM4ENPC1GAAALDH1A1 | |
| SCHEMBL17620537 | 0.81 | LMNA (0.42) | MAPTKDM4ERAD51ALDH1A1GLA | |
| SCHEMBL17620584 | 0.81 | ADORA2A (0.46) | MAPTKDM4ENPC1RAB9ARAD51 | |
| SCHEMBL17620591 | 0.80 | NPC1 (0.44) | MAPTKDM4ENPC1RAB9AAKR1B10 | |
| SCHEMBL17620593 | 0.80 | ADORA2A (0.50) | MAPTKDM4ENPC1RAB9AALDH1A1 | |
| SCHEMBL18396423 | 0.80 | ACHE (0.38) | MAPTRAB9AALDH1A1HSD17B10PDE10A | |
| SCHEMBL17634373 | 0.79 | LMNA (0.38) | MAPTKDM4ERAD51ALDH1A1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10787448-B2 | Indolizino [3,2-C] quinoline-based fluorescent probe | SEOUL NATIONAL UNIVERSITY R & DB FOUNDATION (KR) | 2020-09-29 | — | — | US | disclosed |
| WO-2017014601-A1 | INDOLIZINO [3,2-C] QUINOLINE-BASED FLUORESCENT PROBE | 서울대학교 산학협력단 | 2017-01-26 | — | — | WO | disclosed |
| US-20160108042-A1 | INDOLIZINO[3,2-c]QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CYSTIC FIBROSIS CONTAINING THE SAME AS ACTIVE INGREDIENT | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-04-21 | — | — | US | disclosed |
| US-20160108042-A1 | INDOLIZINO[3,2-c]QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CYSTIC FIBROSIS CONTAINING THE SAME AS ACTIVE INGREDIENT | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-04-21 | — | — | US | disclosed |
| US-20160108042-A1 | INDOLIZINO[3,2-c]QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CYSTIC FIBROSIS CONTAINING THE SAME AS ACTIVE INGREDIENT | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-04-21 | — | — | US | disclosed |
| US-9296751-B1 | Indolizino[3,2-c]quinoline derivatives, pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition for treatment of cystic fibrosis containing the same as active ingredient | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-03-29 | — | — | US | disclosed |
| US-9296751-B1 | Indolizino[3,2-c]quinoline derivatives, pharmaceutically acceptable salt thereof, preparation method thereof and pharmaceutical composition for treatment of cystic fibrosis containing the same as active ingredient | INDUSTRY-ACADEMIC COOPERATION FOUNDATION, YONSEI UNIVERSITY (KR) | 2016-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10787448-B2 | Indolizino [3,2-C] quinoline-based fluorescent probe | DNA2, IRF3, DDB1 | MAPT 1031/4885KDM4E 4624/4885NPC1 1024/4885 |
| US-20160108042-A1 | INDOLIZINO[3,2-c]QUINOLINE DERIVATIVES, PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREOF AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CYSTIC FIBROSIS CONTAINING THE SAME AS ACTIVE INGREDIENT | CFTR, AQP3, AQP1 | MAPT 4884/4885KDM4E 3338/4885NPC1 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.